22288-79-5

Usage

Uses

Used in Pharmaceutical Industry:
METHYL 3-(ACETYLAMINO)-2-THIOPHENECARBOXYLATE is used as a key intermediate for the synthesis of new drugs and bioactive molecules, contributing to the development of innovative pharmaceuticals with potential therapeutic applications.
Used in Agrochemical Industry:
In the agrochemical sector, METHYL 3-(ACETYLAMINO)-2-THIOPHENECARBOXYLATE is utilized as a precursor in the production of agrochemicals, aiding in the creation of effective compounds for pest control and crop protection.
Used in Organic Chemistry Research:
METHYL 3-(ACETYLAMINO)-2-THIOPHENECARBOXYLATE is employed as a reagent in organic synthesis, facilitating the development of complex organic molecules for a variety of applications, including the advancement of materials science and the discovery of novel chemical entities with potential commercial and industrial uses.

InChI:InChI=1/C8H9NO3S/c1-5(10)9-6-3-4-13-7(6)8(11)12-2/h3-4H,1-2H3,(H,9,10)

Upstream product

• 22288-78-4 Methyl 3-aminothiophene-2-carboxylate 
• 75-36-5 acetyl chloride 
• 108-24-7 acetic anhydride 

Downstream Products

• 80621-56-3 methyl 3-amino-4-nitrothiophene-2-carboxylate 
• 18678-13-2 2-methyl-3H-thieno[3,2-d]pyrimidin-4-one 

Relevant academic research and scientific papers

Design, synthesis, and biological evaluation of novel PARP-1 inhibitors based on a 1H-thieno[3,4-d] imidazole-4-carboxamide scaffold

A series of poly(ADP-ribose)polymerase (PARP)-1 inhibitors containing a novel scaffold, the 1H-thieno[3,4-d]imidazole-4-carboxamide moiety, was designed and synthesized. These efforts provided some compounds with relatively good PARP-1 inhibitory activity

THIOENO[3,2-B] PYRIDIN-7-AMINE COMPOUNDS FOR TREATING FAMILIAL DYSAUTONOMIA

The present description relates'to compounds of formula (I) useful for improving pre-mRNA splicing in a cell. In particular, another aspect of the present description relates to substituted thieno[3,2-b]pyridine compounds, forms, and pharmaceutical compos

THIENOPYRIMIDINONE COMPOUNDS

The present disclosure provides compounds that modulate protein function and/or restore protein homeostasis. The disclosure provides methods of modulating protein-mediated diseases, disorders, conditions, or responses. Compositions, including in combination with other therapeutic agents, are provided.

Opioid receptor agonists and application thereof

The invention discloses compounds and salts thereof that can be used as opioid receptor ligands, a preparation method of the compounds, compositions containing the compounds, and a use of the compounds as [mu] opioid receptor agonists; the compounds are used for treatment of [mu] opioid receptor-mediated related diseases, such as pains and pain-related disorders.

Chemical Space Exploration around Thieno[3,2- d]pyrimidin-4(3 H)-one Scaffold Led to a Novel Class of Highly Active Clostridium difficile Inhibitors

Clostridium difficile infection (CDI) is the leading cause of healthcare-associated infection in the United States. Therefore, development of novel treatments for CDI is a high priority. Toward this goal, we began in vitro screening of a structurally diverse in-house library of 67 compounds against two pathogenic C. difficile strains (ATCC BAA 1870 and ATCC 43255), which yielded a hit compound, 2-methyl-8-nitroquinazolin-4(3H)-one (2) with moderate potency (MIC = 312/156 μM). Optimization of 2 gave lead compound 6a (2-methyl-7-nitrothieno[3,2-d]pyrimidin-4(3H)-one) with improved potency (MIC = 19/38 μM), selectivity over normal gut microflora, CC50s > 606 μM against mammalian cell lines, and acceptable stability in simulated gastric and intestinal fluid. Further optimization of 6a at C2-, N3-, C4-, and C7-positions resulted in a library of >50 compounds with MICs ranging from 3 to 800 μM against clinical isolates of C. difficile. Compound 8f (MIC = 3/6 μM) was identified as a promising lead for further optimization.

Thienopyrimidine derivative as an active ingredient a plant disease control agent (by machine translation)

[Problem] in plant disease resistance-inducing gene expression found thienopyrimidine derivative effect, utilizing the thienopyrimidine derivatives, injuries to plant disease organisms[Solution] some of the thienopyrimidine derivatives, such as gene expression in a plant disease-resistance gene to induce PR-a 1, therefore cruciferous vegetables against plant diseases caused by pathogenic bacillus anthracis, exhibiting excellent control effect was found. [Drawing] no (by machine translation)

Discovery of new hit-molecules targeting Plasmodium falciparum through a global SAR study of the 4-substituted-2-trichloromethylquinazoline antiplasmodial scaffold

From 4 antiplasmodial hit-molecules identified in 2-trichloromethylquinazoline series, we conducted a global Structure-Activity relationship (SAR) study involving 26 compounds and covering 5 molecular regions (I – V), aiming at defining the corresponding

Design, synthesis and biological evaluation of novel thieno[3,2-d] pyrimidine derivatives containing diaryl urea moiety as potent antitumor agents

Two series of thieno[3,2-d]pyrimidine derivatives containing diaryl urea moiety were designed, synthesized and evaluated for their biological activity. The preliminary investigation showed that most compounds displayed good to excellent potency against four tested cancer cell lines as compared with GDC-0941 and sorafenib. In particular, the most promising compound 29a showed the most potent antitumor activities with IC50 values of 0.081 μM, 0.058 μM, 0.18 μM, and 0.23 μM against H460, HT-29, MKN-45 and MDA-MB-231 cell lines, respectively. The SAR analyses indicated that compounds with mono-halogen groups at 4-position on the terminal phenyl ring were more active than those with double-halogen groups or methyl groups. In addition, the introduction of chlorine atoms into 6,7-position of thieno[3,2-d]pyrimidine moiety led to a slight decline, but more selective activity against H460 and HT-29 cell lines.

Fragment-based lead discovery: Screening and optimizing fragments for thermolysin inhibition

Fragment-based drug discovery has gained a foothold in today's lead identification processes. We present the application of in silico fragment-based screening for the discovery of novel lead compounds for the metalloendoproteinase thermolysin. We have chosen thermolysin to validate our screening approach as it is a well-studied enzyme and serves as a model system for other proteases. A protein-targeted virtual library was designed and screening was carried out using the program AutoDock. Two fragment hits could be identified. For one of them, the crystal structure in complex with thermolysin is presented. This compound was selected for structure-based optimization of binding affinity and improvement of ligand efficiency, while concomitantly keeping the fragment-like properties of the initial hit. Redesigning the zinc coordination group revealed a novel class of fragments possessing Ki values as low as 128 μm, thus they provide a good starting point for further hit evolution in a tailored lead design.

PTP1B inhibitors

This invention relates to modulating (e.g., inhibiting) protein tyrosine phosphatase 1b (PTP1b).